Vanguard Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.23B | Sell |
|
|||||
|
2025
Q1 | $1.1B | Sell |
|
|||||
|
2024
Q4 | $1.38B | Buy |
|
|||||
|
2024
Q3 | $1.15B | Sell |
|
|||||
|
2024
Q2 | $1.38B | Buy |
|
|||||
|
2024
Q1 | $1.37B | Buy |
|
|||||
|
2023
Q4 | $1.28B | Buy |
|
|||||
|
2023
Q3 | $1.08B | Sell |
|
|||||
|
2023
Q2 | $903M | Sell |
|
|||||
|
2023
Q1 | $971M | Buy |
|
|||||
|
2022
Q4 | $1.12B | Buy |
|
|||||
|
2022
Q3 | $956M | Buy |
|
|||||
|
2022
Q2 | $868M | Buy |
|
|||||
|
2022
Q1 | $823M | Sell |
|
|||||
|
2021
Q4 | $748M | Sell |
|
|||||
|
2021
Q3 | $852M | Sell |
|
|||||
|
2021
Q2 | $874M | Buy |
|
|||||
|
2021
Q1 | $859M | Buy |
|
|||||
|
2020
Q4 | $799M | Buy |
|
|||||
|
2020
Q3 | $785M | Sell |
|
|||||
|
2020
Q2 | $1.03B | Sell |
|
|||||
|
2020
Q1 | $736M | Buy |
|
|||||
|
2019
Q4 | $894M | Buy |
|
|||||
|
2019
Q3 | $740M | Buy |
|
|||||
|
2019
Q2 | $685M | Sell |
|
|||||
|
2019
Q1 | $719M | Buy |
|
|||||
|
2018
Q4 | $577M | Buy |
|
|||||
|
2018
Q3 | $956M | Buy |
|
|||||
|
2018
Q2 | $743M | Buy |
|
|||||
|
2018
Q1 | $606M | Buy |
|
|||||
|
2017
Q4 | $553M | Buy |
|
|||||
|
2017
Q3 | $430M | Buy |
|
|||||
|
2017
Q2 | $318M | Buy |
|
|||||
|
2017
Q1 | $292M | Buy |
|
|||||
|
2016
Q4 | $249M | Buy |
|
|||||
|
2016
Q3 | $318M | Buy |
|
|||||
|
2016
Q2 | $276M | Sell |
|
|||||
|
2016
Q1 | $241M | Buy |
|
|||||
|
2015
Q4 | $336M | Buy |
|
|||||
|
2015
Q3 | $229M | Buy |
|
|||||
|
2015
Q2 | $256M | Buy |
|
|||||
|
2015
Q1 | $157M | Buy |
|
|||||
|
2014
Q4 | $52.8M | Buy |
|
|||||
|
2014
Q3 | $35.8M | Buy |
|
|||||
|
2014
Q2 | $32.9M | Sell |
|
|||||
|
2014
Q1 | $35.8M | Buy |
|
|||||
|
2013
Q4 | $17.6M | Buy |
|
|||||
|
2013
Q3 | $20.7M | Buy |
|
|||||
|
2013
Q2 | $24.2M | Buy |
|